Although the sensitivity of GC cells to chemotherapy agents (cisplatin, 5-FU and paclitaxel) remained unaffected (Fig. 6c), sensitivity to Olaparib and Niraparib was strengthened by YARS depletion (Fig. 6d), suggesting that YARS enhanced homologous recombination hinders the efficacy of PARP inhibitors in GC. This evidence concerns the gene YARS1 and gastric cancer.